Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arranon Phase II Data Appear Adequate For Accelerated Approval, FDA Indicates

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Oncologic Drugs Advisory Committee will consider accelerated approval of GSK's antineoplastic agent nelarabine for T-Cell leukemia and lymphoma on Sept. 14.

You may also be interested in...



Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly

Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.

AstraZeneca Continues Pipeline Expansion Via Two Licensing Deals Totaling $800 Million

Agreements expand the firm’s position in the COPD space, while also entering obesity, diabetes and metabolic syndrome space.

Sunesis To Move Novel Cell-Cycle Inhibitor Forward In Small Cell Lung Cancer

Firm believes the drug, SNS-595, could offer an improved toxicity profile over GSK's Hycamtin.

Topics

UsernamePublicRestriction

Register

PS062870

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel